標的治療と免疫治療を併用した肝細胞がん患者における急性皮膚副作用: 投与量と投与間隔の影響を解明する
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。標的治療と免疫チェックポイント阻害剤 (ICI) で治療された肝細胞癌 (HCC) 患者における非典型的ターゲトイド発疹は,より重度の皮膚副作用 (CADR) を示す. 全用量標的薬剤とICIの短い間隔は,CADRの重症性を増加させる可能性があります.
科学分野
- 腫瘍学
- 皮膚科
- 薬理学について
背景
- 標的薬と免疫チェックポイント阻害剤 (ICI) を併用した治療は,進行性肝細胞癌 (HCC) の主要な治療法である.
- 皮膚発疹の発生率の増加は,この患者集団における重大な臨床的課題です.
- 早期の急性皮膚性副作用 (CADR) を理解することは,この組み合わせ治療の管理に極めて重要です.
研究 の 目的
- 標的薬とICIを併用したHCC患者における急性CADRの臨床的特徴を特徴づける.
- 重度のCADR現象型に関連する潜在的なリスク要因を特定する.
主な方法
- 急性CADRを患った33人のHCC患者の遡及分析.
- 発疹現象型に基づいてマキュロパプル発疹 (MPE) と非典型標的発疹 (ATE) のグループに分類する.
- 臨床的特徴の比較と組み合わせ治療の投与パターンの分析
主要な成果
- 16例のMPEと17例のATEが確認されました.
- ATEグループは,MPEと比較して,遅延期が短く,全身的な症状が多く,重症度が高く,病気の経過が長く,再挑戦の成功率が低いことを示した.
- ATEグループは,全用量標的薬の割合が高く,標的薬とICIの間の間隔が短かった.
結論
- 非典型的ターゲトイド発疹は,併用療法を受けたHCC患者でより重度のCADRを意味する.
- 標的薬の全用量と標的薬とICIの間の短い間隔は,より重度のCADR現象と関連している可能性があります.
関連する概念動画
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...